Chest
Original Research: SarcoidosisA New Tool To Assess Sarcoidosis Severity
Section snippets
Study Population
Sarcoidosis patients (n = 104) were recruited from the granuloma clinic at National Jewish Medical and Research Center between January 2002 and August 2004. All patients met the diagnostic criteria for sarcoidosis established by the American Thoracic Society consensus panel.2 All study subjects were adults between the ages of 18 and 70 years, and provided their informed consent. The consent and the protocol were approved by the National Jewish Medical and Research Center Institutional Review
Characterization of Study Population
The study population consisted of 39 men and 65 women. The demographic features of this group are presented in Table 1. Of note, the race distribution of sarcoidosis patients in this population reflects the local demographics for Colorado. The clinical characteristics of the patient population are summarized in Table 1, Table 2, and reflect a wide range of chest radiograph Scadding stage and organ involvement. All but one subject had pulmonary involvement, with a variety of lung function
Summary
Sarcoidosis is a disease with great phenotypic diversity, with the potential for numerous sites of organ involvement, varying levels of disease activity, and varying degrees of long-term organ dysfunction resulting from periods of active inflammation and, potentially, fibrosis. Our purpose in this study was to create a research tool that would incorporate these many aspects of the disease into a single measure of severity that could be derived from readily available clinical information from a
Acknowledgment
The authors thank Bevin Luna, Juliana Barnard, Trudi Madigan, Deborah Corliss, and Janice Herrell for their role in enrolling patients; Michele Cooper for technical assistance; Lee Newman for insightful discussion and careful review of the manuscript; Mary Solida for her tireless care of the patients; and the patients for their willingness to participate in this work.
References (45)
- et al.
Course and prognosis of sarcoidosis around the world
Am J Med
(1974) - et al.
Low-dose methotrexate therapy for childhood sarcoidosis
J Pediatr
(1997) - et al.
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study; Finnish Pulmonary Sarcoidosis Study Group
Chest
(1999) - et al.
Thalidomide for chronic sarcoidosis
Chest
(2002) - et al.
Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles
Psychosomatics
(2005) - et al.
Sarcoidosis
N Engl J Med
(1997) American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
Am J Respir Crit Care Med
(1999)Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years’ observation
BMJ
(1961)Presentation of sarcoidosis and outcome of pulmonary changes
Dan Med Bull
(1982)- et al.
Sarcoidosis: epidemiology and prognosis: a 15-year European study
Am Rev Respir Dis
(1984)
Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients
Q J Med
The alveolitis of pulmonary sarcoidosis: evaluation of natural history and alveolitis-dependent changes in lung function
Am Rev Respir Dis
Outcome of the treatment for sarcoidosis
Am J Respir Crit Care Med
A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment
Sarcoidosis Vasc Diffuse Lung Dis
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment
Thorax
Epidemiology Standardization Project (American Thoracic Society)
Am Rev Respir Dis
Defining organ involvement in sarcoidosis: the ACCESS proposed instrument; ACCESS Research Group—a case control etiologic study of sarcoidosis
Sarcoidosis Vasc Diffuse Lung Dis
A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis
Am Rev Respir Dis
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography
Am J Respir Crit Care Med
Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients
Eur Respir J
Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients
Eur Respir J
Cited by (56)
Pulmonary Sarcoidosis: Prognostic Factors at Diagnosis in Patients from North of Portugal
2020, Reumatologia ClinicaCitation Excerpt :However, a minority of patients have a chronic course of the disease, sometimes requiring persistent immunosuppressive therapy. It has been suggested that the immunological environment may change to a T-helper 2 response that is associated with a chronic course.3,8,12,13 At diagnosis, besides Löfgren syndrome (LS), we still do not have any reliable and recognized clinical or serum markers that can predict the outcome of a particular patient.
Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients
2020, European Journal of Internal MedicineReprint of: The pathology of pulmonary sarcoidosis: update
2018, Seminars in Diagnostic PathologyCitation Excerpt :In this recent study at the National Jewish Medical and Research Center of 104 sarcoidosis patients, 70% had extra-pulmonary organ involvement. The involved sites included, in decreasing frequency, skin, endocrine organs, extra-thoracic lymph nodes, neurologic sites, eyes, liver, spleen, bone marrow, cardiac, ear/nose/throat, parotid/salivary, muscles, bones/joint, and kidney.37,38 Necrotizing sarcoid granulomatosis (NSG) is both controversial and rare.
Treatment of Sarcoidosis
2015, Clinics in Chest MedicineCutaneous Sarcoidosis: Preamble of a Paucisymptomatic Systemic Disease
2015, Reumatologia Clinica
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
This research was supported by the Parker B. Francis Fellowship and by National Institutes of Health grant M01 RR00051. None of the authors are involved in any organization with a direct financial interest in the subject of the manuscript.